Literature DB >> 11343691

Intravenous administration of ecstasy (3,4-methylendioxymethamphetamine) enhances cortical and striatal acetylcholine release in vivo.

E Acquas1, P Marrocu, A Pisanu, C Cadoni, G Zernig, A Saria, G Di Chiara.   

Abstract

The effect of intravenous administration of 3,4-methylendioxymethamphetamine (MDMA), in a range of doses (0.32-3.2 mg/kg) that have been shown to maintain self-administration behaviour in rats, on in vivo acetylcholine release from rat prefrontal cortex and dorsal striatum was studied by means of microdialysis with vertical concentric probes. Intravenous administration of MDMA dose-dependently increased basal acetylcholine release from the prefrontal cortex to 57+/-21%, 98+/-20%, 102+/-7% and 141+/-14% above baseline, at doses of 0.32, 0.64, 1.0 and 3.2 mg/kg, respectively. MDMA also stimulated striatal acetylcholine release at the dose of 3.2 mg/kg i.v. (the maximal increase being 32+/-3% above baseline) while at the dose of 1 mg/kg i.v., MDMA failed to affect basal acetylcholine output. Administration of MDMA also dose-dependently stimulated behaviour. The results of the present study show that MDMA affects measures of central cholinergic neurotransmission in vivo and suggest that at least some of the psychomotor stimulant actions of MDMA might be positively coupled with an increase in prefrontal cortical and striatal acetylcholine release.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11343691     DOI: 10.1016/s0014-2999(01)00937-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

Review 1.  Regulation of cortical acetylcholine release: insights from in vivo microdialysis studies.

Authors:  Jim R Fadel
Journal:  Behav Brain Res       Date:  2010-02-16       Impact factor: 3.332

2.  3,4-Methylenedioxymethamphetamine enhances the release of acetylcholine in the prefrontal cortex and dorsal hippocampus of the rat.

Authors:  Sunila G Nair; Gary A Gudelsky
Journal:  Psychopharmacology (Berl)       Date:  2005-12-24       Impact factor: 4.530

3.  Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse.

Authors:  William E Fantegrossi; Christina L Kiessel; Richard De la Garza; James H Woods
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

4.  Role of serotonin and/or norepinephrine in the MDMA-induced increase in extracellular glucose and glycogenolysis in the rat brain.

Authors:  Rashida Pachmerhiwala; Nirmal Bhide; Megan Straiko; Gary A Gudelsky
Journal:  Eur J Pharmacol       Date:  2010-07-13       Impact factor: 4.432

Review 5.  Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons.

Authors:  Gary A Gudelsky; Bryan K Yamamoto
Journal:  Pharmacol Biochem Behav       Date:  2007-10-16       Impact factor: 3.533

Review 6.  Developmental effects of 3,4-methylenedioxymethamphetamine: a review.

Authors:  Matthew R Skelton; Michael T Williams; Charles V Vorhees
Journal:  Behav Pharmacol       Date:  2008-03       Impact factor: 2.293

7.  Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice.

Authors:  William E Fantegrossi; Christina Lynn Kiessel; P Tarn Leach; C Van Martin; Rachel Lynn Karabenick; X Chen; Y Ohizumi; Thomas Ullrich; Kenner C Rice; James H Woods
Journal:  Psychopharmacology (Berl)       Date:  2004-01-22       Impact factor: 4.530

8.  The recreational drug ecstasy disrupts the hypothalamic-pituitary-gonadal reproductive axis in adult male rats.

Authors:  Sarah M Dickerson; Deena M Walker; Maria E Reveron; Christine L Duvauchelle; Andrea C Gore
Journal:  Neuroendocrinology       Date:  2008-02-29       Impact factor: 4.914

9.  3,4-methylenedioxyamphetamine upregulates p75 neurotrophin receptor protein expression in the rat brain.

Authors:  Chaomin Wang; Zugui Peng; Weihong Kuang; Hanyu Zheng; Jiang Long; Xue Wang
Journal:  Neural Regen Res       Date:  2012-04-25       Impact factor: 5.135

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.